Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

101575

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions (a) he and (b) officials in his Department have had on ensuring that the payments made by the pharmaceutical industry under the current Pharmaceutical Price Regulation Scheme will be used to improve access to innovative medicines.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212417
answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:</p><p> </p><p> </p><p> </p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;</p><p> </p><p> </p><p> </p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and</p><p> </p><p> </p><p> </p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.</p><p> </p><p> </p><p> </p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.</p><p> </p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients’ health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.</p><p> </p><p> </p><p> </p><p>More generally, the Government’s <em>Strategy for UK Life Sciences</em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212418 212419 question first answered 04/11/2014 17:36:41 answering member 4020 label Biography information for George Freeman previous answer version 25828 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101576

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the (a) process and (b) timelines followed by the NHS to determine a specialised clinical commissioning policy are; and what the roles and responsibilities are of the NHS committees involved.
tabling member constituency	St Austell and Newquay
tabling member printed	Stephen Gilbert
uin	212409
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>Clinical policies are developed by the appropriate service specific clinical reference group and reviewed by the Clinical Prioritisation Advisory Group (CPAG). CPAG then makes a recommendation whether to commission the service or treatment in question. CPAG recommendations are ratified by the Specialised Commissioning Oversight Group (SCOG).</p><p> </p><p> </p><p> </p><p>The length of time to produce a clinical commissioning policy is variable depending on the complexity of the subject area. The timeline is typically between 6-9 months but can be shorter.</p><p> </p><p> </p><p> </p><p>SCOG has operational oversight of specialised commissioning and has delegated authority to make decisions on the recommendations made by CPAG, which provides advice to NHS England about any decision-making that defines access to clinical services. The Directly Commissioned Services Committee, a sub-committee of the NHS England Board, oversees the delivery of directly commissioned services within the overall strategy set by NHS England. The SCOG reports to this committee.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 03/11/2014 17:46:20 answering member 3918 label Biography information for Jane Ellison
tabling member	4101 label Biography information for Stephen Gilbert

101577

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: Haltemprice
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the average waiting time is for talking therapies in (a) Haltemprice and Howden constituency and (b) nationally.
tabling member constituency	Haltemprice and Howden
tabling member printed	Mr David Davis
uin	212411
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>East Riding of Yorkshire Clinical Commissioning Group (CCG) commissions the Improving Access to Psychological Therapies (IAPT) service for the constituency of Haltemprice and Howden.</p><p> </p><p> </p><p> </p><p>The following table shows the mean waiting time for IAPT services across the East Riding of Yorkshire CCG.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p><strong> </strong></p></td><td><p>Mean waiting time (days)</p></td></tr><tr><td><p>England</p></td><td><p>39.5</p></td></tr><tr><td><p>NHS East Riding of Yorkshire CCG</p></td><td><p>150.6</p></td></tr></tbody></table><p> </p><p><em>Note: </em>Entering treatment figures except England totals are rounded to the nearest 5.</p><p> </p><p><strong> </strong></p><p> </p><p><em>Source:</em> Improving Access to Psychological Therapies (IAPT) Dataset</p><p> </p><p><strong> </strong></p><p> </p><p><em>Achieving Better Access to Mental Health Services by 2020</em> sets out action the Government is taking to provide better access to mental health services within the next year, including a national waiting time standard for talking therapies of 75% of people waiting for less than six weeks and 95% of people waiting for less than 18 weeks. It also sets out its vision for further progress by 2020.</p><p> </p><p> </p><p> </p><p>£40 million in additional funding has been identified to enable change in the current financial year, and a further £80 million will be freed up for 2015-16 to support implementation of waiting times in mental health services.</p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 03/11/2014 16:36:08 answering member 1439 label Biography information for Norman Lamb
tabling member	373 label Biography information for Sir David Davis

101578

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	General Practitioners: Recruitment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many GP practices have not been able to replace doctors who have retired in each of the last three years.
tabling member constituency	South Antrim
tabling member printed	Dr William McCrea
uin	212465
answer	answer is ministerial correction date of answer 05/11/2014 answer text <p>The information is not collected by the Department. The last GP Vacancy Survey in England was undertaken by the Health and Social Care Information Centre in 2010. The survey was suspended in 2011 and then discontinued in 2013 following the publication of the Fundamental Review of Data Returns, which aimed to reduce the burden of the collection of data from National Health Service organisations.</p><p> </p><p> </p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 05/11/2014 16:00:06 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	655 label Biography information for Lord McCrea of Magherafelt and Cookstown

101579

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he plans to take to ensure that the payments made by the pharmaceutical industry under the Pharmaceutical Price Regulation Scheme will be apportioned to each of the devolved health administrations, whilst securing that the mechanism in place for determining apportionment ensures that patients in all four constituent parts of the UK receive benefits from the payments made throughout the duration of the scheme.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212420
answer	answer is ministerial correction date of answer 03/11/2014 answer text <p>The Government recognises that the Pharmaceutical Price Regulation Scheme (PPRS) payments that companies make under the 2014 scheme in respect of the United Kingdom need to be allocated to each of the devolved administrations in a fair way. Under the new arrangements introduced as part of the 2014 scheme, the apportionments will be agreed with the devolved administrations each year. The method for apportioning 2014-15 payments has not yet been finalised.</p><p> </p><p> </p><p> </p><p>It is a matter for the devolved health administrations to decide how to use the apportioned payments they receive from the PPRS.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 03/11/2014 17:36:17 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101580

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: Teachers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the number of mindfulness-based (a) cognitive therapy teachers and (b) stress reduction teachers in England.
tabling member constituency	Vale of Clwyd
tabling member printed	Chris Ruane
uin	212428
answer	answer is ministerial correction date of answer 05/11/2014 answer text <p>We do not collect this data centrally.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 05/11/2014 16:04:29 answering member 1439 label Biography information for Norman Lamb
tabling member	534 label Biography information for Chris Ruane

101581

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hospitals: Parking
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will include in the new NHS patient, visitor and staff car parking principles reduced fees for families of long-term hospital patients.
tabling member constituency	South Antrim
tabling member printed	Dr William McCrea
uin	212468
answer	answer is ministerial correction date of answer 05/11/2014 answer text <p>The Department published new National Health Service patient, visitor and staff car parking principles on 23 August 2014. These principles, widely welcomed by a range of charities and organisations representing patients’ interests, made it clear that NHS trusts should provide concessions, including free or reduced charges or caps, to the following groups:</p><p> </p><p> </p><p> </p><p>- people with disabilities;</p><p> </p><p>- frequent outpatient attenders;</p><p> </p><p>- visitors with relatives who are gravely ill;</p><p> </p><p>- visitors to relatives who have an extended stay in hospital; and</p><p> </p><p>- staff working shifts that mean public transport cannot be used.</p><p> </p><p> </p><p> </p><p>Therefore, families of long-term hospital patients should be able to take advantage of the concessions for visitors to relatives who have an extended stay in hospital.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 05/11/2014 15:02:31 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	655 label Biography information for Lord McCrea of Magherafelt and Cookstown

101582

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent discussions he has had with his counterparts in the devolved administrations about the availability of free diabetes tests.
tabling member constituency	South Antrim
tabling member printed	Dr William McCrea
uin	212469
answer	answer is ministerial correction date of answer 05/11/2014 answer text <p>There have been no recent discussions between the Secretary of State and devolved administrations on the availability of free diabetes tests.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 05/11/2014 15:37:39 answering member 3918 label Biography information for Jane Ellison
tabling member	655 label Biography information for Lord McCrea of Magherafelt and Cookstown

101583

registered interest
date	29/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make it his policy to use the Pharmaceutical Price Regulation Scheme to make the UK (a) a global leader in providing patients access to the most innovative appropriate medicines and (b) an attractive place for pharmaceutical companies to locate and invest.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	212419
answer	answer is ministerial correction date of answer 04/11/2014 answer text <p>The 2014 Pharmaceutical Price Regulation Scheme (PPRS) supports the National Health Service to improve patient access to clinically and cost effective medicines in a number of ways:</p><p> </p><p> </p><p> </p><p>- by making medicines more affordable. The PPRS limits growth in the vast majority of spend on branded medicines with industry making payments for spend above the agreed limit;</p><p> </p><p> </p><p> </p><p>- by providing stability and predictability to the Government and the pharmaceutical industry thereby promoting a strong and profitable pharmaceutical industry which encourages innovation and the development of high value treatments; and</p><p> </p><p> </p><p> </p><p>- by a number of agreed measure to improve access to branded medicines commensurate with the outcomes they offer patients.</p><p> </p><p> </p><p> </p><p>Sales of new products are exempt from PPRS payments though still included in the overall limit on growth and the payments made by industry as a whole. This creates a strong in-built incentive in the scheme for companies to innovate.</p><p> </p><p><br> In respect of England, the anticipated PPRS payments for 2014-15 were passed on to NHS England through the Mandate and as such were included within commissioner allocations. In addition, an indicative budget for NHS England for 2015-16 was set on the basis of, amongst other things, the PPRS payment forecast available in 2014. <br> <br> In accordance with normal Government accounting rules and the agreed PPRS, there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients’ health and care. As part of this, following discussion with the Department, NHS England and the Association of the British Pharmaceutical Industry are now pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.</p><p> </p><p> </p><p> </p><p>More generally, the Government’s <em>Strategy for UK Life Sciences</em> sets out an ambitious long-term programme of action to improve the wider environment for pharmaceutical innovation and make the United Kingdom a world-leading place for life sciences investment. The Strategy has delivered £2 billion in industry and private sector investment in the United Kingdom since it was launched in December 2011.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 212417 212418 question first answered 04/11/2014 17:36:41 answering member 4020 label Biography information for George Freeman previous answer version 25832 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

101584

registered interest
date	29/10/2014
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Human Trafficking: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, pursuant to the Answer of 16 October 2014 to question 209897, how many of the 88 minors who are non-UK nationals and were recorded as victims of sexual trafficking in the most recent figures still reside in the UK.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	212426
answer	answer is ministerial correction date of answer 13/11/2014 answer text <p>The Government acknowledge that where children are found to be trafficked, their safety and welfare needs must be addressed as a priority and that child victims require tailored support which addresses their specific needs and vulnerabilities. <br><br>All local agencies have statutory duties to safeguard children as part of their local responsibilities regardless of nationality or immigration status. A <br>child’s welfare is always the overriding consideration. <br><br>Responsibility for the care, protection and accommodation of all child trafficking victims rests with local authorities that have well-established <br>child support arrangements and a statutory duty under the Children Act 2004 to safeguard and promote the welfare of all children in need of protection, including trafficked children regardless of their nationality or immigration status. Under these arrangements, looked after children are provided with access to services to meet all their needs be they in relation to education, accommodation, psychological or health.<br><br>Information as to the location of victims of trafficking, including children, is not held centrally once their status as a victim has been confirmed. <br>This is because the National Crime Agency's UK Human Trafficking Centre has no further role in the process and support is provided by other partners, most notably local authorities in relation to children. The Review of the National Referral Mechanism recommendsthat the Government introduces improved arrangements for tracking victims following an NRM decision and the Government is currently considering its response to the review.<br><br>In January 2014 the Government announced proposals to trial specialist independent advocates for trafficked children. The trial, which began on 8 September 2014, will last for a period of 12 months across 23 local authorities in England. <br><br>The Modern Slavery Bill gives these advocates a statutory basis and the status they need to effectively support and represent the child. The Bill commits the Government to lay a report before Parliament setting out the steps the Government will take in relation to advocates for victims of child trafficking under these powers. Lessons learned from the trials will be detailed in the report, at which point we will be in a better position to assess what works best in supporting and protecting these vulnerable children.</p><p> </p><p> </p><p> </p> answering member constituency Staffordshire Moorlands answering member printed Karen Bradley grouped question UIN 212441 question first answered 13/11/2014 17:27:30 answering member 4110 label Biography information for Dame Karen Bradley
tabling member	298 label Biography information for Steve McCabe